We compared the anti-tumour activity of single agent RMC-7977 to that of the upstream and downstream RAS-MAPK pathway inhibitors RMC-4550 (SHP2 inhibitor) and cobimetinib (MEK inhibitor), respectively, administered as single agents or in combination, in three KRASG12X models. This evidence concerns the gene PTPN11 and neoplasm.